Cannabis–Sedation Associations Differed Between Upper Endoscopy and Colonoscopy
A cannabinoid-use association with higher midazolam requirements appeared during upper endoscopy but not colonoscopy in one prospective cohort. Pooling procedures into one universal sedation rule would obscure that difference.
The cohort separated procedures and drugs
Nasser and colleagues studied 419 outpatients at three endoscopy units using endoscopist-directed conscious sedation. Baseline cannabinoid use was assessed by questionnaire.
Use was associated with receiving at least 5 mg midazolam during upper endoscopy, with an adjusted odds ratio of 2.89 and a 95% confidence interval of 1.19–7.50. The corresponding colonoscopy estimate was 0.89, with an interval of 0.41–1.91.
The null findings constrain the claim
Cannabinoid use was not independently associated with fentanyl use, awareness, discomfort or adverse events. The diphenhydramine and composite-sedation findings also depended on the procedure.
These results do not mean cannabis causes the same dose increase for every sedative. Nor does a nonsignificant comparison establish equivalent requirements between groups.
Association did not identify a tolerance mechanism
This was an observational clinical cohort, not a randomized cannabinoid-exposure or receptor experiment. Procedural demands, patient characteristics and treatment decisions remain relevant to interpretation.
The study supports a procedure-specific association. It does not establish a fixed dose adjustment, prove pharmacological cross-tolerance or determine whether an individual patient will require more medication.
Related: Interpreting cannabis tolerance claims.
Research cited
Nasser Y; Biala S; Chau M; Partridge ACR; Yang JY; Lethebe BC; Stinton LM; Cooray M; Cole MJ; Ma C; Chen YI; Andrews CN; Forbes N Cannabis and cannabinoid research · 2024 · 9(1):310 PMID 36269560 · DOI 10.1089/can.2022.0203. Baseline Cannabinoid Use Is Associated with Increased Sedation Requirements for Outpatient Endoscopy..
